Lantus and Prednisone Interaction: What Happens When You Take Insulin Glargine With a Glucocorticoid

Updated May 25, 2026

Image: HealthRX.com clinical image

Insulin glargine (brand names Lantus, Basaglar, Toujeo) is a long-acting basal insulin analog used to manage type 1 and type 2 diabetes. Prednisone is an oral synthetic glucocorticoid (corticosteroid) prescribed for inflammatory, autoimmune, and allergic conditions, and as immunosuppression after transplant. This article covers what happens when the two are taken together.

Prednisone raises blood glucose through well-established glucocorticoid physiology: it increases hepatic glucose production and reduces insulin-mediated glucose uptake in muscle and fat. Insulin glargine has no meaningful interaction with prednisone through liver enzymes or transporters; glargine is cleared by subcutaneous tissue proteolysis, not cytochrome P450 metabolism. The interaction is pharmacodynamic (one drug opposing the physiologic effect of the other), not pharmacokinetic. It is dose-dependent, expected to appear within roughly one to two days of starting a clinically significant prednisone dose, and reversible as the steroid is tapered. Combining the two drugs is standard practice in diabetes care; the clinical task is anticipating and adjusting insulin, not avoiding the combination.

Is it safe to take Lantus and prednisone together?

Yes, in the sense that the combination is common and manageable. Prednisone does not chemically interact with glargine, and there is no mechanism by which prednisone alters glargine's absorption or breakdown. The real risk is hyperglycemia if insulin is not adjusted upward to compensate for prednisone's glucose-raising effect, and, on the back end of a taper, hypoglycemia if insulin is not brought back down as the steroid dose falls. Lantus prescribing information lists corticosteroids among drugs that can reduce the blood-glucose-lowering effect of insulin, and prednisone labeling warns that insulin or oral hypoglycemic agent requirements in diabetic patients may increase during corticosteroid therapy. Both are FDA-labeled cautions rather than contraindications.

Why does prednisone raise blood sugar?

Three mechanisms are generally accepted in endocrinology and diabetes literature:

Increased hepatic gluconeogenesis and glycogenolysis, driven by glucocorticoid receptor activation in the liver
Reduced peripheral (muscle and adipose) glucose uptake, associated with downregulation of GLUT4 glucose transporters
Some degree of increased glucagon activity, which further promotes hepatic glucose output

These effects are physiologically well characterized for glucocorticoids as a class. The exact magnitude of glucose rise for a given prednisone dose in a given patient is variable and depends on baseline insulin sensitivity, dose, timing, and duration of therapy, so specific numeric predictions (for example, an exact expected percentage change in glucose) should be treated as approximate rather than guaranteed.

How glucose timing tends to shift

Prednisone typically peaks in the blood within a few hours of an oral dose, and its glucose effect tends to lag behind that peak. For patients taking prednisone in the morning, glucose commonly rises most in the afternoon and evening rather than fasting glucose. Basal insulin glargine, which is designed for a relatively flat 24-hour profile, generally covers fasting and overnight glucose reasonably well but does not target a mid-day steroid-driven spike as precisely. This is why some clinicians add a shorter- or intermediate-acting insulin at the time of the steroid dose, in addition to basal glargine, rather than relying on a basal increase alone. Whether that approach is used, and how, is a clinical judgment made by the prescribing clinician based on an individual patient's glucose pattern; it is not something a patient should decide alone.

How insulin doses are typically adjusted (informational, not a personal dosing instruction)

Clinical practice generally treats a prednisone dose in the range of 10 to 20 mg per day as producing a moderate glycemic effect, and doses above that, or pulse-dose corticosteroids, as producing a larger effect that often warrants inpatient-level attention. Reported clinical patterns include an initial basal insulin increase followed by reassessment of glucose over several days, with further titration if pre-meal or bedtime glucose remains elevated, and a proportional decrease in insulin as the prednisone dose is tapered. These patterns come from clinical practice and observational reports rather than a single definitive trial, and the exact percentage adjustments used in day-to-day care vary by institution and clinician.

This article does not provide an individual dosing plan. Insulin adjustments during corticosteroid therapy should be set and revised by the prescribing clinician or a diabetes care team, based on actual glucose readings, kidney function, hypoglycemia history, and the planned steroid taper.

Monitoring during co-administration

Reasonable, widely recommended monitoring during concurrent prednisone and glargine therapy includes:

Fingerstick glucose checks at least several times a day (commonly fasting, before lunch, before dinner, and at bedtime), with pre-dinner readings often most informative for morning prednisone dosing
Watching for symptoms of significant hyperglycemia (excess thirst, urination, fatigue) and, in people with type 1 diabetes or on SGLT2 inhibitors, symptoms of diabetic ketoacidosis
Reassessing glucose control again after the steroid course ends, since insulin needs typically fall as prednisone is tapered
Serum potassium monitoring may be relevant in some patients, since both insulin and glucocorticoids affect potassium distribution, but the need for this should be determined by the treating clinician based on dose and clinical context

The American Diabetes Association's Standards of Care address glycemic management in hospitalized and glucocorticoid-treated patients as part of its annually updated guideline; readers and clinicians should check the current-year edition rather than relying on numbers from any single prior year, since thresholds and recommendations are revised periodically.

New-onset diabetes during prednisone therapy

People without a prior diabetes diagnosis can develop hyperglycemia, and in some cases sustained diabetes, during systemic glucocorticoid therapy. Reported incidence figures for steroid-induced hyperglycemia vary widely across studies depending on dose, treatment duration, and how hyperglycemia is defined, so no single incidence percentage should be treated as a precise, generalizable number without checking the specific study population it comes from. Recognized risk factors include older age, obesity, a family history of type 2 diabetes, and prediabetes-range HbA1c before starting steroids. Patients starting a glucocorticoid course expected to last two weeks or longer, especially those with risk factors, are commonly screened with a fasting or random glucose check early in treatment; if glucose is significantly elevated, insulin is often preferred over oral agents because it can be titrated quickly.

Duration and course type change the picture

Short steroid bursts (days, for example an asthma or gout flare): expect a sharp but temporary glucose rise, with a return toward baseline within days of stopping. Insulin increases here should be treated as temporary and reversed promptly, since a stalled increase can cause hypoglycemia after the steroid clears.
Chronic or long-term prednisone (for example, in rheumatoid arthritis or after transplant): insulin needs generally reach a new, elevated plateau within one to two weeks and remain there as long as the steroid dose is stable. This usually calls for a more durable adjustment to the regimen rather than a temporary patch, decided with the treating clinician.
Steroids with a longer half-life, such as dexamethasone, tend to produce more sustained, around-the-clock hyperglycemia rather than the more clearly timed peak seen with prednisone, which can change how a clinician structures the insulin regimen.

Other medications that change the picture

Some drugs commonly taken alongside prednisone and insulin can worsen or blunt the glucose effect, and are worth mentioning to a prescriber or pharmacist:

Thiazide diuretics and calcineurin inhibitors (tacrolimus, cyclosporine, often used in transplant patients already on prednisone) can independently worsen glucose control
Metformin, GLP-1 receptor agonists, and SGLT2 inhibitors (kidney function permitting) can partially offset glucocorticoid-driven hyperglycemia and are sometimes continued or added alongside insulin during steroid therapy
Beta-blockers can mask the warning symptoms of hypoglycemia, which matters especially during a steroid taper when insulin needs are falling

This list is not exhaustive. A pharmacist review of the full medication list is reasonable any time prednisone is added to an insulin regimen.

Special populations

Type 1 diabetes: no endogenous insulin reserve exists to buffer the glucocorticoid effect, so glucose can rise quickly and insulin adjustments (both basal and mealtime) are often needed sooner and more aggressively, always under clinician guidance.
Older adults: this group is more prone to steroid-induced hyperglycemia but also more vulnerable to hypoglycemia if insulin is increased too far or not reduced promptly during a taper. Glycemic targets during active steroid therapy in older or frail patients are often relaxed compared with usual outpatient targets, as a clinical judgment made case by case.
Pregnancy: antenatal corticosteroids (commonly betamethasone, a different glucocorticoid than prednisone) given for fetal lung maturity can cause a fast, marked glucose rise in insulin-treated patients. Monitoring frequency and insulin adjustment in this setting should follow obstetric and endocrinology guidance specific to the pregnancy, not general outpatient protocols.

When to seek urgent care

Contact a prescriber promptly, or seek urgent or emergency care, if any of the following occur:

Blood glucose repeatedly above roughly 300 mg/dL despite following an adjusted insulin plan
Symptoms suggesting diabetic ketoacidosis: nausea, vomiting, abdominal pain, rapid or labored breathing, confusion
Blood glucose below 54 mg/dL (a level generally considered clinically significant hypoglycemia), particularly during a steroid taper
New muscle weakness, palpitations, or cramping, which can reflect a potassium shift

What patients and clinicians should discuss before starting

That glucose is expected to rise, and this reflects the pharmacology of the steroid, not a failure of diabetes self-management
A specific glucose monitoring schedule to follow while on prednisone
Who to contact and how quickly, if glucose readings exceed an agreed threshold
How and when insulin will be reduced as prednisone is tapered, since over-correction after the steroid is stopped is a recognized cause of hypoglycemia
Access to a correction plan or rapid-acting insulin for breakthrough hyperglycemia, and glucose tablets or fast-acting carbohydrate in case of hypoglycemia during the taper

Evidence boundary: what is established, what is plausible, what is not

Established: prednisone and other systemic glucocorticoids cause dose-dependent hyperglycemia through increased hepatic glucose output and reduced peripheral glucose uptake; this effect is pharmacodynamic and reverses as the steroid is tapered; insulin glargine has no cytochrome P450-based interaction with prednisone; both FDA labels flag the combination as requiring glucose monitoring and possible dose adjustment.

Plausible but not precisely quantified for every patient: the exact percentage insulin increase needed for a given prednisone dose; the exact incidence of new-onset steroid diabetes for a specific patient's risk profile; the benefit of adding NPH or another intermediate-acting insulin versus increasing basal glargine alone, which varies by regimen and glucose pattern.

Not established from the material reviewed here: precise numeric interaction severity scores, specific percentage figures for glucose area-under-curve change, or exact incidence rates cited without a verifiable, matching primary source. Any such number appearing elsewhere should be checked against the original study before being treated as a general fact.

Evidence-status assessment: Lantus plus prednisone

Claim	Status	Basis	What to verify before relying on it
No CYP/P-glycoprotein interaction between glargine and prednisone	Established	Basic pharmacology of glargine's clearance route; supported by FDA labeling context	No action needed beyond confirming current label language
Prednisone reduces insulin effectiveness via increased hepatic glucose output and reduced peripheral uptake	Established	Core glucocorticoid physiology, consistent with FDA labeling caution	Confirm mechanism detail against current pharmacology references if used in patient education material
Glargine dose adjustment is typically needed once prednisone reaches a moderate-to-high dose	Guideline-consistent, dose-response direction established; exact percentages not verified here	General diabetes and endocrinology clinical practice	Confirm specific percentage targets against current ADA Standards of Care and institutional protocol before publishing as a fixed number
Afternoon/evening glucose rises more than fasting glucose with morning prednisone dosing	Plausible and pharmacokinetically consistent	Timing of prednisone absorption relative to its delayed glucose effect	Confirm with glucose monitoring in the individual patient; timing shifts with evening dosing or long-acting steroids
Specific incidence rates for new-onset steroid diabetes (for example, a fixed percentage)	Not established for general use	Reported incidence varies widely by study population and steroid regimen	Do not publish a single incidence figure without citing and checking the exact source study and its population
Named-clinician quotations about steroid-induced hyperglycemia management	Removed pending verification	Could not confirm attribution or exact wording from available source material	Verify with a documented, dated primary source before reinstating any direct quote
Fixed numeric interaction "severity rating" from a specific database	Not verified here	Database classifications change and were not independently confirmed	Check current Lexicomp, Micromedex, or equivalent database entry directly before citing a rating

Frequently asked questions

Can I take Lantus with prednisone?

Yes. This is a routine combination in diabetes care. It usually requires a proactive insulin adjustment and closer glucose monitoring while both drugs are being taken, decided with your prescriber.

Is it safe to combine Lantus and prednisone?

It is generally safe when monitored. The main risk is uncontrolled hyperglycemia if insulin is not increased in response to prednisone, and hypoglycemia if insulin is not reduced again as prednisone is tapered.

Why does prednisone raise blood sugar?

Prednisone increases glucose production by the liver, reduces glucose uptake by muscle and fat tissue, and may increase glucagon activity. Together these push blood glucose higher, and someone on insulin cannot compensate for this the way a person with normal insulin secretion can.

When does blood sugar peak after taking prednisone?

For a morning dose, glucose commonly peaks in the afternoon to early evening, following prednisone's absorption and its downstream effect on liver glucose output. Evening dosing tends to shift the glucose effect toward overnight and morning instead.

Do I need to reduce my Lantus dose when tapering off prednisone?

Often yes, since insulin needs generally fall as the steroid dose falls, but the exact adjustment should be set by the prescriber based on glucose trends, not applied as a fixed formula at home.

Can prednisone cause diabetes in someone who didn't have it before?

Yes, new-onset hyperglycemia and, in some patients, diabetes can develop during systemic glucocorticoid therapy, particularly in people who are older, have obesity, or have prediabetes. Exact risk depends on dose, duration, and individual risk factors.

What other drugs interact with Lantus in a way that matters here?

Thiazide diuretics and calcineurin inhibitors can worsen glucose control; metformin, GLP-1 receptor agonists, and SGLT2 inhibitors can partially offset it; and beta-blockers can hide the warning signs of low blood sugar. A pharmacist review of the full medication list is worthwhile.

References

American Diabetes Association Professional Practice Committee. Standards of Care in Diabetes (check current annual edition). Diabetes Care, journal issue page

Additional claims referenced in earlier drafts of this material (specific incidence percentages, named-clinician quotations, and individual trial results) could not be matched to a verifiable primary source during this review and have been removed or narrowed rather than presented as fact. A qualified clinical reviewer should confirm remaining numeric ranges against current primary literature and institutional protocol before publication.